CHICAGO--(BUSINESS WIRE)--GE HealthCare announces the commencement, and its leading industrial role, in Thera4Care, an initiative aimed at revolutionizing the use of theranostics to broaden patient access in Europe. The €25.3 million project gathers 29 partners from top European academic and clinical sites, small and medium-sized enterprises, and patient advocacy groups..

芝加哥--（商业新闻短讯）--GE HealthCare宣布Thera4Care项目的启动及其行业领先地位，该项目旨在彻底改变治疗诊断的使用方式，以拓宽欧洲患者的就诊范围。这项耗资2530万欧元的项目汇集了来自欧洲顶级学术和临床网站、中小型企业和患者倡导团体的29位合作伙伴。。

Cancer is the leading cause of death worldwide, accounting for nearly ten million deaths in 2022. By 2050, the global burden is expected to grow to 35 million new cancer cases[1], which is due, in part, to population growth and aging. As a breakthrough approach to treating cancer, theranostics integrates imaging diagnostics and targeted therapeutics for personalized treatment of disease.

癌症是全球死亡的主要原因，2022年死亡人数近千万。到2050年，全球负担预计将增加到3500万新的癌症病例，部分原因是人口增长和老龄化。作为治疗癌症的突破性方法，theranostics将成像诊断和靶向治疗相结合，以个性化治疗疾病。

It uses molecular imaging technologies to visualize tumor receptors and, if present, deliver a radioactive drug to selectively target the tumor cells..

它使用分子成像技术可视化肿瘤受体，如果存在，则提供放射性药物以选择性靶向肿瘤细胞。。

Theranostics is already used to treat a number of late-stage prostate and neuroendocrine cancers, but it is only available in a handful of specialized centers. There is critical incremental clinical need to develop new, innovative radiotheranostics to expand clinical indications of theranostics as well as to expand its use to community centers for broader patient access..

Theranostics已被用于治疗许多晚期前列腺癌和神经内分泌癌，但它仅在少数专业中心可用。临床上迫切需要开发新的创新放射治疗学，以扩大治疗学的临床适应症，并将其扩展到社区中心，以扩大患者的使用范围。。

Thera4Care aims to expand the use of theranostics in Europe by creating, implementing, and disseminating standardized, scalable methods for the production, detection, and monitoring of key theranostic isotopes, from the manufacturing and early delivery of diagnostics through to therapy. The project will strengthen the use and adoption of radiology-based diagnostics and therapies and focus on disease areas (prostate, ovarian, pancreas cancers and sarcomas), aligning with the growing significance of multi-modal radiotheranostics solutions.

Thera4Care旨在通过创建、实施和传播标准化、可扩展的方法来生产、检测和监测关键的治疗诊断同位素，从诊断的制造和早期交付到治疗，从而扩大欧洲治疗诊断的使用。该项目将加强基于放射学的诊断和治疗的使用和采用，并将重点放在疾病领域（前列腺癌，卵巢癌，胰腺癌和肉瘤），以适应多模式放射治疗解决方案日益重要的意义。

GE HealthCare technology already supports the steps needed to deliver on the theranostics pathway, encompassing cyclotrons and PET and SPECT imaging scanners to advanced visualization solutions, digital solutions, and consulting services..

GE HealthCare technology已经支持实现治疗诊断途径所需的步骤，包括回旋加速器、PET和SPECT成像扫描仪，以及先进的可视化解决方案、数字解决方案和咨询服务。。

“We are thrilled to play a leading role in Thera4Care, a unique collaboration of academic and industry partners who share a common goal to advance connected, personalized and compassionate cancer care,” said Dr. Ben Newton, GE HealthCare’s general manager for Oncology Solutions. “Our collective efforts are designed to improve healthcare system readiness for this rapidly growing field of precision medicine.”.

GE HealthCare肿瘤学解决方案总经理Ben Newton博士表示：“我们很高兴在Thera4Care中发挥领导作用，Thera4Care是学术界和业界合作伙伴的独特合作伙伴，他们有一个共同的目标，即推进互联、个性化和富有同情心的癌症护理。”。“我们的集体努力旨在提高医疗保健系统对这一快速增长的精准医学领域的准备程度。”。

With the help of the Thera4Care grant, GE HealthCare and the sponsors aim to:

在Thera4Care赠款的帮助下，GE HealthCare和赞助商的目标是：

Expand the European network of copper producing isotope good manufacturing practices (GMP) sites using a common hardware and software platform with identical and reproducible methods.

使用具有相同和可重复方法的通用硬件和软件平台，扩展欧洲铜生产同位素良好生产规范（GMP）网站网络。

Develop next-generation SPECT-CT imaging scanners to enable imaging with a wide range of alpha emitters.

开发下一代SPECT-CT成像扫描仪，以便能够使用各种α发射器进行成像。

Build artificial intelligence (AI)-enabled imaging and multi-modal theranostic clinical decision support with predictive analytics capabilities, initially targeting prostate cancer to ensure optimized patient outcomes.

建立具有预测分析能力的人工智能（AI）成像和多模式治疗诊断临床决策支持，最初针对前列腺癌，以确保优化患者预后。

Enhance AI-based tumor quantitation by developing a methodology framework for personalized dosimetry.

通过开发个性化剂量测定的方法框架，增强基于AI的肿瘤定量。

Thera4Care brings together partners from 14 European countries and the United States. The consortium's main academic partners include Università Cattolica del Sacro Cuore & Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Italy), Erasmus University (Netherlands), Jules Bordet Institute (Belgium), UniKlinik Essen (Germany), Gregorio Maranon General University Hospital (Spain) and Institut de Cancérologie de l'Ouest (France)..

Thera4Care汇集了来自14个欧洲国家和美国的合作伙伴。该联盟的主要学术合作伙伴包括天主教大学（UniversitàCattolica del Sacro Cuore）、阿戈斯蒂诺·杰梅利大学警察临床基金会（Fondazione Policlinico Universitario Agostino Gemelli IRCCS）（意大利）、伊拉斯谟大学（荷兰）、朱尔斯·博德特研究所（比利时）、埃森大学（德国）、格雷戈里奥·马拉农综合大学医院（西班牙）和西部癌症研究所（法国）。

The project is co-funded under the Horizon Europe framework, and part of the Innovative Health Initiative (IHI), a public-private partnership between the European Union and the European life science industries. The Joint Undertaking (IHI JU) under grant agreement #101172788 receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe and Thera4Care contributing partners.

该项目是在地平线欧洲框架下共同资助的，也是创新健康倡议（IHI）的一部分，该倡议是欧盟和欧洲生命科学行业之间的公私合作伙伴关系。根据赠款协议#101172788的联合事业（IHI JU）得到了欧盟地平线欧洲研究与创新计划以及COCIR，EFPIA，Europa Bío，MedTech Europe，欧洲疫苗和Thera4Care贡献合作伙伴的支持。

The grant agreement was signed on October 1, 2024, and runs through the next five years. For more information please visit the IHI website or Thera4Care project page here..

该赠款协议于2024年10月1日签署，将持续五年。。。

To learn more about GE HealthCare’s portfolio of Theranostics solutions, please visit gehealthcare.com or the company’s booth (Booth H20, Level 0) at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany from October 19-23.

要了解更多有关GE HealthCare的治疗诊断解决方案组合的信息，请访问gehealthcare.com或10月19日至23日在德国汉堡举行的欧洲核医学协会（EANM）大会上该公司的展位（展位H20，0级）。

About GE HealthCare Technologies Inc.

关于GE HealthCare Technologies Inc。

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier.

GE HealthCare是全球领先的医疗技术、药物诊断和数字解决方案创新者，致力于提供集成的解决方案、服务和数据分析，使医院更高效、临床医生更有效、治疗更精确，患者更健康、更快乐。

Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring.

GE HealthCare为患者和提供者服务了125多年，正在推进个性化、互联化和富有同情心的护理，同时简化患者跨越护理路径的旅程。我们的成像、超声波、患者护理解决方案和药物诊断业务共同帮助改善患者护理，从诊断到治疗再到监测。

We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits..

。。

Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

在LinkedIn、X、Facebook、Instagram和Insights上关注我们的最新消息，或访问我们的网站https://www.gehealthcare.com/了解更多信息。

1 https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services

1https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services